FDA Commissioner Nominee Open About Science On Acetaminophen Safety, Mum On Trump’s Claim
During confirmation hearing, Heidi Overton assures Senate HELP Committee members that as commissioner she would follow science in decisions on products subject to FDA’s oversight while carefully avoiding questioning the president’s statements.
HBW Insight - September 28, 2026

Coherus Looks To Sell Off Final Biosimilars Assets
After already divesting its major biosimilars product franchises, Coherus Oncology has initiated a process to sell off the remaining assets related to the legacy business after exiting the biosimilars sector last year.
Generics Bulletin - September 28, 2026

EASD: Abbott, Dexcom Studies Show CGMs Reduce Mortality But Lack Awareness
Abbott and Dexcom release data highlighting the benefits of continuous glucose monitoring as the companies push for broader reimbursement.
Medtech Insight - September 28, 2026

Strategic Intent: Boehringer Ingelheim’s Brian Hilberdink on Launching Into the GLP-1 Era
Boehringer Ingelheim's US Human Pharma president on navigating a major launch cycle, competing in obesity without chasing pounds, and playing the long game as a private company.
In Vivo - September 28, 2026

UK’s Landmark CBD Authorizations May Be Short-Lived As EU Deal Looms
Britain's first CBD authorizations may not outlast the UK-EU food deal. FSA chair Susan Jebb has told manufacturers to seek EU approval in parallel, warning that exemptions will be "exceptional and few."
HBW Insight - September 28, 2026

Sofinnova Partners Closed $93.4M MD Start IV Fund With Plans To Launch 6 To 8 Start-Ups
Sofinnova Partners closed an oversubscribed (€82m) $93.4m to fund for six to eight medtech companies with a focus on cardiovascular and AI-powered technologies, according to partner Anne Osdoit.
Medtech Insight - September 28, 2026

People On The Move: Appointments At PAGB, SIRIO Europe, Lonza
A round-up of the latest moves in Europe's consumer health sector: Reckitt leader elected vice president of PAGB; new general manager of SIRIO Europe named; Lonza appoints global head of communications.
HBW Insight - September 28, 2026

US Industry Sees Opportunity In FDA User-Fee Reauthorizations
The reauthorizations of generic and biosimilar user-fee programs GDUFA and BsUFA bring opportunities and progress for the US off-patent sector, industry association the AAM believes.
Generics Bulletin - September 28, 2026

Stada Builds Its Biosimilars Future With Multi-Product SBP Alliance – Including Pembrolizumab
Stada has advanced its biosimilars interests through a partnership with China’s SBP that includes a proposed pembrolizumab rival to Keytruda – as well as up to three additional molecules – in European and CIS markets, with options for the US and Gulf states.
Generics Bulletin - September 28, 2026

B7-H3 ADC Field Opens As Merck & Co. Pulls US Filing
The second drug candidate from Merck & Co.’s ADC mega-deal with Daiichi Sankyo has hit a stumbling block with the US FDA, after the agency deemed its BLA insufficient for an accelerated approval. Hopes are now pinned on the IDeate-Lung02 Phase III trial.
Scrip - September 28, 2026

FDA Consumer Health Advisory: Supplements Escape California’s ‘Use By’ Labeling Change
What's happening, why it matters and what's next at FDA. This edition explores California's decision to exempt dietary supplements from new labeling requirements for food; FDA's optimism on reducing the need for animal testing; and an NAD review of an ear wax removal product.
HBW Insight - September 28, 2026

Japan Addresses Non-OTC Legal Gray Area - But It’s Not As Simple As It Looks
Planned law revisions in Japan banning the dispensing of normally prescription drugs without a prescription prompt a lawsuit from pharmacies operating in the currently grey legal area.
Pink Sheet - September 28, 2026

Is The UK Becoming A Cautionary Tale For Off-Patent Markets?
The UK off-patent sector is showing the strain of a decade of price compression, with over 60% of generic volume now reimbursed at under £1 for a month's supply. Medicines UK chair Paul Burden argues the market has passed the point of sustainability.
In Vivo - September 28, 2026

AI-Powered CT Imaging: New Opportunities For Non-Invasive CAD Diagnosis
Global diagnostic imaging major Royal Philips is using partnership approaches to achieve clinical validation of its computed tomography-based integrated care pathway for patients with coronary artery disease.
In Vivo - September 28, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: China’s transforming effect; Novo’s new strategy; Roche’s obesity contender; Amgen’s Sjögren’s win; and potential Chinese blockbusters.
Scrip - September 28, 2026

Three Topics Dominated US FDA Commissioner Nominee Overton’s Senate Hearing
Heidi Overton's FDA confirmation hearing was less about running the agency and more about navigating three political minefields: mifepristone, vaccines and flavored vapes.
HBW Insight - September 28, 2026